FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016683885> ?p ?o ?g. }

• W2016683885 endingPage "363" @default.
• W2016683885 startingPage "354" @default.
• W2016683885 abstract "Background Gastric adenocarcinoma is a leading cause of cancer mortality. The role of dopamine and cAMP regulated phosphoprotein MW 32 kDa (DARPP-32) overexpression in the gastric tumorigenesis cascade remains unclear. Methods The expression of DARPP-32 in the multistep carcinogenesis cascade was examined using immunohistochemistry analysis on 533 samples. The contribution of DARPP-32 in cellular transformation and molecular signaling was investigated using NIH3T3, AGS, and SNU16 cells. Results The composite expression score (CES), calculated from immunostaining patterns, increased significantly from normal or gastritis to metaplasia, dysplasia, and adenocarcinoma (P < .001). In patients with normal stomach or gastritis and tumor samples, a 76% and 77% chance, respectively, was found (P < .001) that CES was higher in the tumor. High median CES correlated with well- or moderately differentiated (P = .03) gastric adenocarcinomas. NIH3T3 cells transfected with DARPP-32 demonstrated increased levels of phospho-AKT and a 5-fold increase in the number of foci as compared with the control (P = .02). DARPP-32 expression in AGS cells led to increased protein levels of phospho-AKT and BCL-2. For validation, the knockdown of endogenous DARPP-32 expression in SNU16 cells using shRNA resulted in decreased levels of phospho-AKT phosphorylation and BCL-2. Conclusion Our results suggest that DARPP-32 overexpression may participate in the transition to intestinal metaplasia and in the progression to neoplasia. The ability of DARPP-32 to transform NIH3T3 cells and to regulate AKT and BCL-2 underscores its possible oncogenic potential. Gastric adenocarcinoma is a leading cause of cancer mortality. The role of dopamine and cAMP regulated phosphoprotein MW 32 kDa (DARPP-32) overexpression in the gastric tumorigenesis cascade remains unclear. The expression of DARPP-32 in the multistep carcinogenesis cascade was examined using immunohistochemistry analysis on 533 samples. The contribution of DARPP-32 in cellular transformation and molecular signaling was investigated using NIH3T3, AGS, and SNU16 cells. The composite expression score (CES), calculated from immunostaining patterns, increased significantly from normal or gastritis to metaplasia, dysplasia, and adenocarcinoma (P < .001). In patients with normal stomach or gastritis and tumor samples, a 76% and 77% chance, respectively, was found (P < .001) that CES was higher in the tumor. High median CES correlated with well- or moderately differentiated (P = .03) gastric adenocarcinomas. NIH3T3 cells transfected with DARPP-32 demonstrated increased levels of phospho-AKT and a 5-fold increase in the number of foci as compared with the control (P = .02). DARPP-32 expression in AGS cells led to increased protein levels of phospho-AKT and BCL-2. For validation, the knockdown of endogenous DARPP-32 expression in SNU16 cells using shRNA resulted in decreased levels of phospho-AKT phosphorylation and BCL-2. Our results suggest that DARPP-32 overexpression may participate in the transition to intestinal metaplasia and in the progression to neoplasia. The ability of DARPP-32 to transform NIH3T3 cells and to regulate AKT and BCL-2 underscores its possible oncogenic potential." @default.
• W2016683885 created "2016-06-24" @default.
• W2016683885 creator A5001099941 @default.
• W2016683885 creator A5004112104 @default.
• W2016683885 creator A5004330175 @default.
• W2016683885 creator A5009350218 @default.
• W2016683885 creator A5014370129 @default.
• W2016683885 creator A5019526114 @default.
• W2016683885 creator A5025250725 @default.
• W2016683885 creator A5048600723 @default.
• W2016683885 creator A5071298606 @default.
• W2016683885 creator A5087826096 @default.
• W2016683885 date "2010-08-01" @default.
• W2016683885 modified "2023-10-18" @default.
• W2016683885 title "Dopamine and cAMP regulated phosphoprotein MW 32 kDa is overexpressed in early stages of gastric tumorigenesis" @default.
• W2016683885 cites W1782967980 @default.
• W2016683885 cites W1820344370 @default.
• W2016683885 cites W1963604703 @default.
• W2016683885 cites W1980157504 @default.
• W2016683885 cites W1980778328 @default.
• W2016683885 cites W1989227905 @default.
• W2016683885 cites W2001258296 @default.
• W2016683885 cites W2003605454 @default.
• W2016683885 cites W2020830322 @default.
• W2016683885 cites W2022215139 @default.
• W2016683885 cites W2025678968 @default.
• W2016683885 cites W2041393241 @default.
• W2016683885 cites W2043103956 @default.
• W2016683885 cites W2046024015 @default.
• W2016683885 cites W2046454404 @default.
• W2016683885 cites W2049418722 @default.
• W2016683885 cites W2061009167 @default.
• W2016683885 cites W2073883180 @default.
• W2016683885 cites W2094079572 @default.
• W2016683885 cites W2133154503 @default.
• W2016683885 cites W2139156128 @default.
• W2016683885 cites W2143854315 @default.
• W2016683885 cites W2164463173 @default.
• W2016683885 cites W2170278621 @default.
• W2016683885 cites W4211113621 @default.
• W2016683885 doi "https://doi.org/10.1016/j.surg.2010.05.011" @default.
• W2016683885 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2919779" @default.
• W2016683885 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20580047" @default.
• W2016683885 hasPublicationYear "2010" @default.
• W2016683885 type Work @default.
• W2016683885 sameAs 2016683885 @default.
• W2016683885 citedByCount "22" @default.
• W2016683885 countsByYear W20166838852012 @default.
• W2016683885 countsByYear W20166838852013 @default.
• W2016683885 countsByYear W20166838852015 @default.
• W2016683885 countsByYear W20166838852016 @default.
• W2016683885 countsByYear W20166838852019 @default.
• W2016683885 countsByYear W20166838852020 @default.
• W2016683885 countsByYear W20166838852021 @default.
• W2016683885 countsByYear W20166838852023 @default.
• W2016683885 crossrefType "journal-article" @default.
• W2016683885 hasAuthorship W2016683885A5001099941 @default.
• W2016683885 hasAuthorship W2016683885A5004112104 @default.
• W2016683885 hasAuthorship W2016683885A5004330175 @default.
• W2016683885 hasAuthorship W2016683885A5009350218 @default.
• W2016683885 hasAuthorship W2016683885A5014370129 @default.
• W2016683885 hasAuthorship W2016683885A5019526114 @default.
• W2016683885 hasAuthorship W2016683885A5025250725 @default.
• W2016683885 hasAuthorship W2016683885A5048600723 @default.
• W2016683885 hasAuthorship W2016683885A5071298606 @default.
• W2016683885 hasAuthorship W2016683885A5087826096 @default.
• W2016683885 hasBestOaLocation W20166838852 @default.
• W2016683885 hasConcept C11960822 @default.
• W2016683885 hasConcept C121608353 @default.
• W2016683885 hasConcept C126322002 @default.
• W2016683885 hasConcept C142724271 @default.
• W2016683885 hasConcept C204232928 @default.
• W2016683885 hasConcept C2775894508 @default.
• W2016683885 hasConcept C2776497702 @default.
• W2016683885 hasConcept C2777061661 @default.
• W2016683885 hasConcept C2781182431 @default.
• W2016683885 hasConcept C502942594 @default.
• W2016683885 hasConcept C555283112 @default.
• W2016683885 hasConcept C71924100 @default.
• W2016683885 hasConcept C75217442 @default.
• W2016683885 hasConcept C86803240 @default.
• W2016683885 hasConcept C95444343 @default.
• W2016683885 hasConceptScore W2016683885C11960822 @default.
• W2016683885 hasConceptScore W2016683885C121608353 @default.
• W2016683885 hasConceptScore W2016683885C126322002 @default.
• W2016683885 hasConceptScore W2016683885C142724271 @default.
• W2016683885 hasConceptScore W2016683885C204232928 @default.
• W2016683885 hasConceptScore W2016683885C2775894508 @default.
• W2016683885 hasConceptScore W2016683885C2776497702 @default.
• W2016683885 hasConceptScore W2016683885C2777061661 @default.
• W2016683885 hasConceptScore W2016683885C2781182431 @default.
• W2016683885 hasConceptScore W2016683885C502942594 @default.
• W2016683885 hasConceptScore W2016683885C555283112 @default.
• W2016683885 hasConceptScore W2016683885C71924100 @default.
• W2016683885 hasConceptScore W2016683885C75217442 @default.
• W2016683885 hasConceptScore W2016683885C86803240 @default.
• W2016683885 hasConceptScore W2016683885C95444343 @default.
• W2016683885 hasIssue "2" @default.

• next